IGHE and Alzheimer disease: The downregulation of CXCL13 attenuated the clinical symptoms associated with AD (Figure 10C), prevented DNCB from increasing ß-hexosaminidase activity (Figure 10D), and prevented DNCB from increasing serum PGE2 level, serum IgE level, and the amount of histamine released in BALB/c mouse (Figure 10E).